nShift: Belgian Companies Must Act Fast to Meet Minimum Delivery Options Requirements
6.9.2024 11:15:00 CEST | Business Wire | Press release
Following the introduction of new legislation, nShift is offering a time-limited 25% off promotion for new customers in Belgium
Belgium’s online retailers have just 16 days to comply with a new legal requirement to provide their customers with greater delivery choice. New legislation demands that from 21 September, webshops and ecommerce retailers in Belgium must provide at least two methods for the delivery of products to consumers. Retailers will be free to choose the delivery method but (at least) one of the options is encouraged to be eco-friendly.
It’s why nShift, the global leader in experience and delivery management (DMXM) is introducing a new and limited time offer designed to help retailers comply with the new law and offer a better customer experience. New customers in Belgium will receive 25% off a subscription to any of nShift’s solutions for six months.
Sean-Sherwin Smith, Product Director, Post Purchase at nShift said, “The new law marks a major shift in how online retailers will operate across Belgium. The new rule emphasizes sustainability and customer convenience. It marks a significant change in the regulatory landscape and means multi-carrier capability must be central to how retailers operate in the future.
"Sustainability is a core part of nShift’s offer. Our 1000+ carrier library features numerous sustainable last-mile solutions. Our Checkout functionality makes it easier to quickly badge and label more sustainable delivery options so shoppers can quickly find what they are looking for.”
Multi-carrier capability
Retailers will be able to respond to these changes more easily and efficiently if they work with a delivery management partner that offers multi-carrier capabilities. Beyond meeting the new legal requirement, working with a variety of carriers means retailers can offer real choice to shoppers, gain the agility to adapt to shifting consumer demand, and grow their business. Multi-carrier deliveries enable retailers to:
- Offer a range of delivery options - shoppers expect to find the shipping solution they seek
- Boost delivery capacity - making it easier to respond to increased demand
- Improve delivery quality and efficiency – by gaining real data about the performance of each carrier
- Grow beyond borders - shipping internationally requires relationships with carrier companies that serve the relevant territories
- Build the brand and remarket to customers – by taking control of customer communications
Multi-carrier capability is at the heart of nShift’s DMXM suite of solutions. It provides enterprise-grade delivery management with a library of 1000+ ready-made carrier connections. nShift can connect retailers and consumers to over one million PUDO (pick up / drop off) locations. Retailers can automate the carrier-booking and label-printing process. This helps retailers send out more parcels, work with more carriers, and tightly control the delivery experience.
Sherwin-Smith concluded, “Businesses affected by the new law need to act fast but it’s also important they make the necessary adjustments in a scalable and sensible way. They must work with a partner that offers choice and convenience, particularly when it comes to eco-friendly carriers and emissions tracking capabilities.”
For more information on the offer or to find out how nShift could help your business with its multi-carrier offering, please visit our website, www.nshift.com.
About nShift
nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.
nShift. Worry less. Ship smarter. www.nshift.com
Notes to editors
Under Article VI.45/2 of the Code of Economic Law, webshops will be required to offer at least two delivery methods, including one that is eco-friendly.
This offer is not available to existing customers and cannot be combined with any other discount or promotion. The offer is valid from 00:01 05 September 2024 until midnight on 31 December 2024.
Full subscription agreement will outline contractual terms, Customer will be granted optional termination 90 days from “Start Date”. A minimum of 14 days’ notice of termination must be given. This email does not represent contractual obligation. Promotion excludes existing “Track” service customers; customers with an existing signed “Track” subscription agreement. nShift AB standard terms and conditions apply. Promotional offer will run until 30th November 2023. nShift reserves the right to close promotional offer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906823045/en/
Contacts
James Ellerington:
James Ellerington:
James.Ellerington@fourteenforty.uk / (+44) 07725 534941
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom